Azitra, Inc. (NYSEAMERICAN:AZTR) Short Interest Down 51.3% in May

Azitra, Inc. (NYSEAMERICAN:AZTR) was the target of a significant decline in short interest in May. As of May 29th, there was short interest totaling 61,636 shares, a decline of 51.3% from the May 14th total of 126,538 shares. Based on an average trading volume of 629,575 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.4% of the company’s stock are short sold.

Azitra Price Performance

NYSEAMERICAN AZTR opened at $0.21 on Friday. The stock’s fifty day moving average price is $0.22 and its 200-day moving average price is $0.25. Azitra has a 12 month low of $0.10 and a 12 month high of $2.40.

Azitra (NYSEAMERICAN:AZTR) last posted its earnings results on Wednesday, May 13th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.24). On average, equities research analysts forecast that Azitra will post -0.25 earnings per share for the current year.

About Azitra

Azitra Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem.

The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance.